Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Visit
ESMO 2022
;
🎥@evaciruelos of @hospital12Oct discusses Phase II ACROSS-TROP2 study exploring predictive biomarkers and resistance mechanisms in HR+/HER2- advanced #breastcancer. Exciting prospects at #ESMOBreast2024:
➡️⬅️
@myESMO
ACROSS-TROP2: identifying predictive biomarkers of SG in HR+/HER2- breast cancer
Eva Ciruelos, MD, PhD, Hospital 12 de Octubre, Madrid, Spain, gives an overview of the rationale and trial design ...
ow.ly
#ESMOBreast24 | Always a pleasure to speak to @Icro_Meattini, Orit Kaidar-Person and Philip Poortmans on radiation updates in #breastcancer, including RT in the setting of pCR.
Hear their insights and more at http://VJOncology.com🖱️
@myESMO @OncoAlert #bcsm
#ESMOBreast24 | We spoke to Sung-Bae Kim, who gave us updated OS findings on Destiny-Breast02, which highlights the benefits of T-DXd in HER2+ mBC
If you missed the session, visit http://VJOncology.com to see his talk and more in #breastcancer!
@myESMO #bcsm @Oncoalert
Join us for our Post-ASCO 2024 Highlights 📣
Featuring presentations & panel discussions on selected abstracts from #ASCO 2024 🔦
Agendas available soon 📝
REGISTER 👉 https://www.vjoncology.com/feature/post-asco-2024-highlights/
#ASCO24 @DrSanjayPopat @tompowles1 @stolaney1 @LizzySmyth1
#ESMOBreast24 | We had the opportunity to catch up with @DrSGraff, who spoke on:
⭐1L CDK4/6 inhibitor trial data in HR+/HER2− #breastcancer
⭐Sequencing CDK4/6 inhibitors in the clinic
⭐The benefits of multidisciplinary care
@myESMO #bcsm @Oncoalert
ESMO 2022
🎥@evaciruelos of @hospital12Oct discusses Phase II ACROSS-TROP2 study exploring predictive biomarkers and resistance mechanisms in HR+/HER2- advanced #breastcancer. Exciting prospects at #ESMOBreast2024:
➡️⬅️
@myESMO
ACROSS-TROP2: identifying predictive biomarkers of SG in HR+/HER2- breast cancer
Eva Ciruelos, MD, PhD, Hospital 12 de Octubre, Madrid, Spain, gives an overview of the rationale and trial design ...
ow.ly
#ESMOBreast24 | Always a pleasure to speak to @Icro_Meattini, Orit Kaidar-Person and Philip Poortmans on radiation updates in #breastcancer, including RT in the setting of pCR.
Hear their insights and more at http://VJOncology.com🖱️
@myESMO @OncoAlert #bcsm
#ESMOBreast24 | We spoke to Sung-Bae Kim, who gave us updated OS findings on Destiny-Breast02, which highlights the benefits of T-DXd in HER2+ mBC
If you missed the session, visit http://VJOncology.com to see his talk and more in #breastcancer!
@myESMO #bcsm @Oncoalert
Join us for our Post-ASCO 2024 Highlights 📣
Featuring presentations & panel discussions on selected abstracts from #ASCO 2024 🔦
Agendas available soon 📝
REGISTER 👉 https://www.vjoncology.com/feature/post-asco-2024-highlights/
#ASCO24 @DrSanjayPopat @tompowles1 @stolaney1 @LizzySmyth1
#ESMOBreast24 | We had the opportunity to catch up with @DrSGraff, who spoke on:
⭐1L CDK4/6 inhibitor trial data in HR+/HER2− #breastcancer
⭐Sequencing CDK4/6 inhibitors in the clinic
⭐The benefits of multidisciplinary care
@myESMO #bcsm @Oncoalert
Latest videos from ESMO 2022!
View all
GU at ESMO 2022!
View all
GI at ESMO 2022!
View all
Breast cancer at ESMO 2022!
View all
Stay tuned for interviews with the following doctors and more...
